CenterBook Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

CenterBook Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Buy	+33,915	New	+$1.86M	0.1%	239
2026 Q1	–	Sell	-35,718	Closed	-$2.12M	–	659
2025 Q4	$2.12M	Buy	+35,718	New	+$1.94M	0.1%	257
2023 Q4	–	Sell	-10,534	Closed	-$932K	–	397
2023 Q3	$932K	Sell	10,534 -2,776	-21%	-$247K	0.12%	257
2023 Q2	$1.15M	Buy	13,310 +4,365	+49%	+$411K	0.14%	220
2023 Q1	$870K	Buy	8,945 +507	+6%	+$52.6K	0.12%	253
2022 Q4	$873K	Sell	8,438 -2,079	-20%	-$195K	0.14%	217
2022 Q3	$892K	Buy	10,517 +1,895	+22%	+$169K	0.17%	202
2022 Q2	$715K	Buy	8,622 +1,480	+21%	+$118K	0.15%	229
2022 Q1	$551K	Sell	7,142 -2,567	-26%	-$215K	0.2%	187
2021 Q4	$858K	Buy	+9,709	New	+$801K	0.5%	57

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CenterBook Partners's BMRN Position: Q2 2026 in Review

CenterBook Partners opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 33,915 shares worth $1.94M. The stake represents 0.1% of the portfolio and ranks #239 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in BMRN as recently as Q4 2025.

CenterBook Partners first reported a position in BMRN in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.12M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

CenterBook Partners held 33,915 shares of BioMarin Pharmaceuticals worth $1.94M as of Q2 2026.
BioMarin Pharmaceuticals was a new CenterBook Partners position in Q2 2026.
BioMarin Pharmaceuticals made up 0.1% of CenterBook Partners's portfolio in Q2 2026, its #239 holding.
CenterBook Partners first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
CenterBook Partners's BioMarin Pharmaceuticals position peaked at $2.12M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.